Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,310,326 papers from all fields of science
Search
Sign In
Create Free Account
epacadostat
Known as:
1,2,5-Oxadiazole-3-carboximidamide, 4-((2-((Aminosulfonyl)amino)ethyl)amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-, (C(Z))-
An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (1)
INCB024360
NCIt Antineoplastic Agent Terminology
Broader (2)
Oximes
Sulfonamides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers
Shoujun Chen
,
Fengtao Liu
,
+31 authors
Daxing Gao
Clinical research
2018
Corpus ID: 81756040
Indoleamine-2,3-dioxygenase (IDO1) is well-recognized as an important target for immunotherapeutic intervention. Growing…
Expand
2018
2018
Abstract 2736: Preclinical pharmacologic and pharmacodynamic studies of a novel and potent IDO1 inhibitor D-0751
Yaolin Wang
,
Shi Zhe
,
Zixing Han
,
Zhenwu Wang
,
Yueheng Jiang
,
D. Xing
Immunology
2018
Corpus ID: 81752010
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme that catalyzes the degradation of the essential amino acid L…
Expand
2018
2018
Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
D. Levitan
2018
Corpus ID: 146113078
At AACR 2018, Dr. Aung Naing of MD Anderson presented ECHO-203, the first data on epacadostat in combination with an anti–PD-L1…
Expand
2018
2018
Epacadostat plus Pembrolizumab Is Well Tolerated in a Phase I Trial.
Cancer Discovery
2018
Corpus ID: 52924968
Epacadostat plus pembrolizumab achieved responses in 40% of patients with advanced solid tumors.
2017
2017
Eric Rubin
LY Na
,
S. Si
Nature reviews. Drug discovery
2017
Corpus ID: 11125238
Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations…
Expand
2017
2017
Epacadostat/Pembrolizumab Promising in Advanced Bladder Cancer in Early Trial
D. Levitan
2017
Corpus ID: 182866148
The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with…
Expand
2017
2017
Epacadostat Plus Pembrolizumab Shows Early Promise in Advanced RCC
B. Furlow
2017
Corpus ID: 149572246
Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for…
Expand
2017
2017
Highlights of This Issue
Clinical Cancer Research
2017
Corpus ID: 41292163
Last prior treatment The enzyme indoleamine 2,3dioxygenase-1 (IDO1), which catabolizes tryptophan degradation, can promote tumor…
Expand
2016
2016
Kutanes CD30-positives großzelliges anaplastisches Lymphom — ein Fall
Doris Berger
Im Focus Onkologie
2016
Corpus ID: 171305545
Neue Targets im Blick Allerdings, so Larkin, führten neue molekulare Angrispunkte, wie z. B. die Indolamin-2,3-Dioxygenase (IDO…
Expand
2015
2015
Epacadostat/Pembrolizumab Combo Shows Activity in Advanced Melanoma
M. Fuerst
2015
Corpus ID: 164693520
The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma…
Expand